Protara Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-57.4M | $-44.6M | $-40.4M | $-66.0M | $-47.3M | $-34.0M | $-7.8M | $-20.7M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $362.0K | $332.0K | $341.0K | $248.0K | $117.0K | $103.0K | $16.0K | $115.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $3.8M | $4.1M | $6.1M | $6.7M | $10.4M | $9.7M | $424.0K | $3.4M |
| Net Cash from Operating Activities | $-56.4M | $-35.8M | $-37.6M | $-26.5M | $-34.5M | $-23.4M | $-5.0M | $-23.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $94.0K | $63.0K | $45.0K | $120.0K | $596.0K | $884.0K | $475.0K | $119.0K |
| Business Acquisitions | — | — | — | — | — | $-3.7M | — | — |
| Net Cash from Investing Activities | $-139.5M | $19.2M | $53.1M | $15.0M | $-98.2M | $2.8M | $-475.0K | $18.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | $91.0K | $90.0K | $228.0K | — | — | — |
| Net Cash from Financing Activities | $82.7M | $139.9M | $-91.0K | $-90.0K | $-228.0K | $189.4M | $500.0K | $3.0M |
| Net Change in Cash | — | — | — | — | — | — | $-13.2M | $-1.8M |
| Free Cash Flow | $-56.5M | $-35.9M | $-37.6M | $-26.6M | $-35.1M | $-24.3M | $-5.5M | $-23.4M |